I believe the mechanism of action of Trofinetide is barely understood. Could that be the reason of the lack of traction?
Is there greater interest in the Vanderbilt program because the analysts have a much better understanding of the mechanism of action of highly selective positive allosteric modulators of the M1 subtype of muscarinic acetyl hauling receptor? I doubt it.
Other possible reasons for lack of interest in trofinetide from US analysts and institutions:
It’s not an American-developed drug; nor is Neuren an American biotech.
Trofinetide is perhaps perceived as almost identical to IGF-1. Boston Children’s Hospital IGF-1 in Rett syndrome Phase 2 trial failed – not only was significant improvement not demonstrated, but some parameters worsened.
Trofinetide failed in the US-based Phase 2 trial in TBI.
ACADIA TALKS TROFINETIDE, page-70
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |